

# Hepatology

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

Volume 51 • Number 2

February 2010

## Introduction To New Section

- 363 **Diagnostic and Therapeutic Advances in Hepatology: A New Feature in the *Journal***  
*Patrick S. Kamath and Keith D. Lindor*

## Comments From the Editors

- 364 **Growing Old Gracefully: Caring for the 90-Year-Old Liver in the 40-Year-Old Transplant Recipient**  
*Saul J. Karpen*

## Editorials

- 366 **Thiazolidinedione Therapy for Nonalcoholic Steatohepatitis: Go, Stop, or Proceed with Caution?**  
*Stephen A. Harrison*

(See Article on Page 445)

- 370 **Transient Elastography in Nonalcoholic Fatty Liver Disease: Making Sense of Echos**  
*Leon Adams*

(See Article on Page 454)

- 373 **Long-Term Mortality in Nonalcoholic Fatty Liver Disease: Is Liver Histology of Any Prognostic Significance?**  
*Paul Angulo*

(See Article on Page 595)

- 376 **Making the Liver What It Is: The Many Targets of the Transcriptional Regulator HNF4 $\alpha$**   
*Klaus H. Kaestner*

(See Article on Page 642)

\**Human Study*

**Cover Figure:** Magnetic resonance image of an obese adult, demonstrating the increase in subcutaneous fat (yellow), and visualizing other organ systems, including muscle (brown), bone, internal organs and brain. A histological micrograph (20 $\times$  magnification) of a normal liver (left image) and a fatty liver (seen as pale droplets within liver cells in the right image) has been superimposed over the liver area. Excessive liver fat is a robust marker of metabolic dysfunction (e.g. insulin resistance, dyslipidemia, diabetes), independent of percent body fat and fat distribution. See article on page 679.

## Original Articles

### VIRAL HEPATITIS

- 378 **Selection-Driven Immune Escape Is Not a Significant Factor in the Failure of CD4 T Cell Responses in Persistent Hepatitis C Virus Infection**  
*Michael J. Fuller, Naglaa H. Shoukry, Toshifumi Gushima, David G. Bowen, Benoit Callendret, Katherine J. Campbell, Dana L. Hasselschwert, Austin L. Hughes, and Christopher M. Walker*
- 388 **\*Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis**  
*Savino Bruno, Mitchell L. Shiffman, Stuart K. Roberts, Edward J. Gane, Diethelm Messinger, Stephanos J. Hadziyannis, and Patrick Marcellin*
- 398 **The Heme Oxygenase 1 Product Biliverdin Interferes with Hepatitis C Virus Replication by Increasing Antiviral Interferon Response**  
*Elisabeth Lehmann, Walid Hamdy El-Tantawy, Matthias Ocker, Ralf Bartenschlager, Volker Lohmann, Said Hashemolhosseini, Gisa Tiegs, and Gabriele Sass*
- 405 **Cost-Effectiveness of Nationwide Hepatitis B Catch-up Vaccination Among Children and Adolescents in China**  
*David W. Hutton, Samuel K. So, and Margaret L. Brandeau*
- 415 **\*Lamivudine Maintenance Beyond One Year After HBeAg Seroconversion Is a Major Factor for Sustained Virologic Response in HBeAg-Positive Chronic Hepatitis B**  
*Hyun Woong Lee, Heon Ju Lee, Jae Seok Hwang, Joo Hyun Sohn, Jae Young Jang, Ki Jun Han, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong Han Paik, Chun Kyon Lee, Kwan Sik Lee, Chae Yoon Chon, and Kwang-Hyub Han*
- 422 **\*Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B**  
*Ting-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, and Uchenna Iloeje*

# CONTENTS

- 431 **Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008**

David B. Rein, Sarah B. Lesesne, Ann O'Fallon, and Cindy M. Weinbaum

- 435 **\*Age-Specific Prognosis Following Spontaneous Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B**

Yi-Cheng Chen, Chia-Ming Chu, and Yun-Fan Liaw

## STEATOHEPATITIS/METABOLIC LIVER DISEASE

- 445 **\*Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial**

Vlad Ratziu, Frédéric Charlotte, Carole Bernhardt, Philippe Girál, Marine Halbron, Gilles LeNaour, Agnès Hartmann-Heurtier, Eric Bruckert, and Thierry Poynard, for the LIDO Study Group

(See Editorial on Page 366)

- 454 **\*Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease**

Vincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, Juliette Foucher, Henry Lik-Yuen Chan, Brigitte Le Bail, Paul Cheung-Lung Choi, Mathurin Kowo, Anthony Wing-Hung Chan, Wassil Merrouche, Joseph Jao-Yiu Sung, and Victor de Lédinghen

(See Editorial on page 370)

- 463 **Lack of Interleukin-6/Glycoprotein 130/Signal Transducers and Activators of Transcription-3 Signaling in Hepatocytes Predisposes to Liver Steatosis and Injury in Mice**

Daniela C. Kroy, Naiara Beraza, Darjus F. Tschaharganeh, Leif E. Sander, Stephanie Erschfeld, Arne Giebeler, Christian Liedtke, Hermann E. Wasmuth, Christian Trautwein, and Konrad L. Streetz

- 474 **\*Toxicant-Associated Steatohepatitis In Vinyl Chloride Workers**

Matt Cave, Keith Cameron Falkner, Mukunda Ray, Swati Joshi-Barve, Guy Brock, Rehan Khan, Marjorie Bon Homme, and Craig J. McClain

- 482 **\*Gamma-Glutamyltransferase and Disability Pension: A Cohort Study of Construction Workers in Germany**

Heiner Claessen, Hermann Brenner, Christoph Drath, and Volker Arndt

- 491 **\*Variability in Ethanol Biodisposition in Whites Is Modulated by Polymorphisms in the ADH1B and ADH1C Genes**

Carmen Martínez, Segismundo Galván, Elena Garcia-Martin, María I. Ramos, Yolanda Gutiérrez-Martín, and José A.G. Agúndez

- 501 **\*Hemochromatosis in Italy in the Last 30 Years: Role of Genetic and Acquired Factors**

Anna Ludovica Fracanzani, Alberto Piperno, Luca Valenti, Mirella Fraquelli, Sabina Coletti, Alessandra Maraschi, Dario Consonni, Enzo Coviello, Dario Conte, and Silvia Fargion

- 511 **Kupffer Cells Promote Hepatic Steatosis Via Interleukin-1 $\beta$ -Dependent Suppression of Peroxisome Proliferator-Activated Receptor  $\alpha$  Activity**

Rinke Stienstra, Fredy Saudale, Caroline Duval, Shohreh Keshkar, Johanna E. M. Groener, Nico van Rooijen, Bart Staels, Sander Kersten, and Michael Müller

## HEPATOBIILIARY MALIGNANCIES

- 523 **Down-Regulation of Connective Tissue Growth Factor by Inhibition of Transforming Growth Factor  $\beta$  Blocks the Tumor-Stroma Cross-Talk and Tumor Progression in Hepatocellular Carcinoma**

Antonio Mazzocca, Emilia Fransvea, Francesco Dituri, Luigi Lupo, Salvatore Antonaci, and Gianluigi Giannelli

- 535 **\*Liver Cancer: EphrinA2 Promotes Tumorigenicity Through Rac1/Akt/NF- $\kappa$ B Signaling Pathway**

Yu-Xiong Feng, Jiang-Sha Zhao, Jing-Jing Li, Tao Wang, Shu-Qun Cheng, Yunfei Yuan, Fudi Wang, Xiao-Fan Wang, and Dong Xie

- 545 **Expression and Functional Significance of Twist1 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry**

Tao Sun, Nan Zhao, Xiu-lan Zhao, Qiang Gu, Shi-wu Zhang, Na Che, Xing-hui Wang, Jing Du, Yi-xin Liu, and Bao-cun Sun

- 557 **\*Loss of Hepatocyte Nuclear Factor 1 $\alpha$  Function in Human Hepatocellular Adenomas Leads to Aberrant Activation of Signaling Pathways Involved in Tumorigenesis**

Laura Pelletier, Sandra Rebouissou, Alain Paris, Estelle Rathahao-Paris, Elisabeth Perdu, Paulette Bioulac-Sage, Sandrine Imbeaud, and Jessica Zucman-Rossi

## AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE

- 567 **\*CX3CL1 (Fractalkine): A Signpost for Biliary Inflammation in Primary Biliary Cirrhosis**

Shinji Shimoda, Kenichi Harada, Hiroaki Niuro, Akinobu Taketomi, Yoshihiko Maehara, Koichi Tsuneyama, Kentaro Kikuchi, Yasuni Nakanuma, Ian R. Mackay, M. Eric Gershwin, and Koichi Akashi

# CONTENTS

## LIVER FAILURE/CIRRHOSIS/ PORTAL HYPERTENSION

- 576 **Systematic Review of Randomized Trials on Vasoconstrictor Drugs for Hepatorenal Syndrome**  
*Lise L. Gluud, Kurt Christensen, Erik Christensen, and Aleksander Krag*
- 585 **\*Prognostic Value of Ishak Fibrosis Stage: Findings from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial**  
*James E. Everhart, Elizabeth C. Wright, Zachary D. Goodman, Jules L. Dienstag, John C. Hoefs, David E. Kleiner, Marc G. Ghany, A. Scott Mills, S. Russell Nash, Sugantha Govindarajan, Thomas E. Rogers, Joel K. Greenson, Elizabeth M. Brunt, Herbert L. Bonkovsky, Chihiro Morishima, Heather J. Litman, the HALT-C Trial Group*
- 595 **\*Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up**  
*Cecilia Söderberg, Per Stål, Johan Askling, Hans Glaumann, Greger Lindberg, Joel Marmur, and Rolf Hultcrantz*  
(See Editorial on Page 373)
- 603 **Chronic Administration of Valproic Acid Inhibits Activation of Mouse Hepatic Stellate Cells *In Vitro* and *In Vivo***  
*Inge Mannaerts, Nele R. Nuytten, Vera Rogiers, Karin Vanderkerken, Leo A. van Grunsven, and Albert Geerts*

## LIVER INJURY/REGENERATION

- 615 **Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events**  
*Craig Lammert, Einar Bjornsson, Anna Niklasson, and Naga Chalasani*
- 621 **Toll-Like Receptor 9 Inhibition Confers Protection from Liver Ischemia-Reperfusion Injury**  
*Zubin M. Bamboat, Vinod P. Balachandran, Lee M. Ocuin, Hebron Obaid, George Plitas, and Ronald P. DeMatteo*

## LIVER BIOLOGY/ PATHOBIOLOGY

- 633 **The Homeobox Gene *Hex* Regulates Hepatocyte Differentiation from Embryonic Stem Cell-Derived Endoderm**  
*Atsushi Kubo, Yon Hui Kim, Stefan Irion, Shogo Kasuda, Mitsuaki Takeuchi, Kazuo Ohashi, Masayuki Iwano, Yoshiko Dohi, Yoshihiko Saito, Ralph Snodgrass, and Gordon Keller*

- 642 **Integrated Approach for the Identification of Human Hepatocyte Nuclear Factor 4 $\alpha$  Target Genes Using Protein Binding Microarrays**  
*Eugene Bolotin, Hailing Liao, Tuong Chi Ta, Chuhu Yang, Wendy Hwang-Verslues, Jane R. Evans, Tao Jiang, and Frances M. Sladek*  
(See Editorial on Page 376)

## Rapid Communication

- 654 **Huh-7: A Human "Hemochromatotic" Cell Line**  
*Chiara Vecchi, Giuliana Montosi, and Antonello Pietrangelo*

## AASLD Practice Guidelines

- 660 **Diagnosis and Management of Primary Sclerosing Cholangitis**  
*Roger Chapman, Johan Fevery, Anthony Kalloo, David M. Nagorney, Kirsten Muir, Boberg, Benjamin Shneider, and Gregory J. Gores*

## Reviews

- 679 **Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications**  
*Elisa Fabbrini, Shelby Sullivan, and Samuel Klein*
- 690 **Contemporary Clinical Research of Traditional Chinese Medicines for Chronic Hepatitis B in China: An Analytical Review**  
*Lingyi Zhang, Guqi Wang, Weihong Hou, Ping Li, Andrea Dulin, and Herbert L. Bonkovsky*

## Diagnostic and Therapeutic Advances in Hepatology

- 699 **Tolvaptan and Hyponatremia in a Patient with Cirrhosis**  
*Thomas D. Boyer*

## Hepatology Elsewhere

- 703 **Snipping Away at Hepatitis C**  
*Nicholas A. Shackel, David G. Bowen, and Geoffrey W. McCaughan*
- 705 **Biting the Iron Bullet: Endoplasmic Reticulum Stress Adds the Pain of Hepcidin to Chronic Liver Disease**  
*Donald J. Messner and Kris V. Kowdley*
- 707 **A Glimpse of Future Hepatitis C Virus Treatment Paradigms**  
*Norah Terrault and Mandana Khalili*

## Image of The Month

- 711 **The Bright Liver of Glycogenic Hepatopathy**  
*Seth Sweetser and Robert E. Kraichely*

# CONTENTS

## Correspondence

- 713 Extrahepatic Conditions Associated with Primary Biliary Cirrhosis
- 713 The Preferable Treatment for Cirrhotic Portal Vein Thrombosis: Anticoagulation or Transjugular Intrahepatic Portosystemic Shunt?
- 714 Toll-Like Receptor 4: A Starting Point for Proinflammatory Signals in Fatty Liver Disease
- 715 Noninvasive Assessment of Liver Disease Severity With Liver Fat Score and CK-18 In NAFLD: Prognostic Value of Liver Fat Equation Goes Beyond Hepatic Fat Estimation
- 717 Serum Markers of Hepatocyte Apoptosis: Current Terminology and Predictability in Clinical Practice
- 718 Comment on "Angiotensin-Converting-Enzyme 2 Inhibits Liver Fibrosis in Mice"
- 718 Carvedilol Versus Variceal Band Ligation for Prevention of the First Variceal Bleed
- 719 Metformin in Chronic Hepatitis C Virus Hepatitis: Caution Needed with Sex-Based Subgroup Analysis
- 720 From Liver Markers to Life Expectancy
- 721 Clodronate Liposomes: All Sites of Injection Are Not Equal
- 723 Radiofrequency Ablation Must Be Assessed by Pathological Methods